Reference : Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/10993/36511
Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers.
English
Raulf, N. [> >]
Lucarelli, Philippe mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Life Science Research Unit]
Thavaraj, S. [> >]
Brown, S. [> >]
Vicencio, J. M. [> >]
Sauter, Thomas mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Tavassoli, M. [> >]
2018
European journal of cancer (Oxford, England : 1990)
102
52-68
Yes (verified by ORBilu)
International
0959-8049
1879-0852
England
[en] Annexin A1 (ANXA1) ; Cetuximab ; EGFR phosphorylation ; EGFR signalling ; Exosomes ; Formyl peptide receptor ; Head and neck cancer ; miR-196a
[en] BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer with approximately half a million cases diagnosed each year worldwide. HNSCC has a poor survival rate which has not improved for over 30 years. The molecular pathogenesis of HNSCCs remains largely unresolved; there is high prevalence of p53 mutations and EGFR overexpression; however, the contribution of these molecular changes to disease development and/or progression remains unknown. We have recently identified microRNA miR-196a to be highly overexpressed in HNSCC with poor prognosis. Oncogenic miR-196a directly targets Annexin A1 (ANXA1). Although increased ANXA1 expression levels have been associated with breast cancer development, its role in HNSCC is debatable and its functional contribution to HNSCC development remains unclear. METHODS: ANXA1 mRNA and protein expression levels were determined by RNA Seq analysis and immunohistochemistry, respectively. Gain- and loss-of-function studies were performed to analyse the effects of ANXA1 modulation on cell proliferation, mechanism of activation of EGFR signalling as well as on exosome production and exosomal phospho-EGFR. RESULTS: ANXA1 was found to be downregulated in head and neck cancer tissues, both at mRNA and protein level. Its anti-proliferative effects were mediated through the intracellular form of the protein. Importantly, ANXA1 downregulation resulted in increased phosphorylation and activity of EGFR and its downstream PI3K-AKT signalling. Additionally, ANXA1 modulation affected exosome production and influenced the release of exosomal phospho-EGFR. CONCLUSIONS: ANXA1 acts as a tumour suppressor in HNSCC. It is involved in the regulation of EGFR activity and exosomal phospho-EGFR release and could be an important prognostic biomarker.
http://hdl.handle.net/10993/36511
Copyright (c) 2018 Elsevier Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
raulf2018.pdfPublisher postprint3.01 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.